TIA生物标记物通过蛋白质组学(I11-1A)

文摘

背景:血管神经的“圣杯”之一是TIA血清标志物。首页质量spectrometry-based蛋白质组学,一个独特的,公正的方法来识别候选蛋白,被用来测试瞬态神经症状患者的血清生物标志物的脑缺血。方法:前瞻性的瞬态神经症状患者。质谱法进行血清样本,对人类Uniport数据库搜索结果。三个候选蛋白被发现,这些蛋白质测定的血清浓度ELISA在第二批前瞻性的病人。学生的学习任务是用于比较。Benjamini-Hochberg的错误发现率控制程序多重比较蛋白质组屏幕调整决定意义。结果:TIA患者(n = 20),轻微中风(n = 15)和控制(如偏头痛、癫痫、n = 12)参加第一组。血浆铜蓝蛋白,补充组件C8γ(C8γ)和血小板碱性蛋白(PBP)缺血性样本之间的明显不同(TIA和轻微中风)和控制(p = 0.0001, p = 0.00027, p = 0.00105)。第二批TIA患者(n = 21),轻微中风(n = 20)和控制(n = 12)血清进行了测试。 PBP serum concentrations were increased in the ischemic samples compared to control (for TIA and stroke, p= 0.046, for TIA alone, p=0.019). Ceruloplasmin trended towards increased concentrations in the ischemic groups (p=0.127), and an insignificant increase in C8γ (p=0.44) was found. Conclusions: PBP has been identified as potential serum biomarker for TIA. Larger sample size may find that ceruloplasmin is an additional candidate. Ultimately, a panel of proteins may be required. Larger studies are needed to determine the validity of these proteins in clinical use.

披露:乔治博士没有披露。Mlynash博士没有披露。亚当斯博士没有披露。郭博士没有披露。坎普博士没有披露。加西亚博士没有披露。阿尔伯斯博士已经收到个人补偿的活动与基因泰克,inc .)和Lundbeck公司研究它是一家美国公司作为顾问。Olivot博士没有披露。